{"id":"W4406868895","doi":"10.1200/jco.2025.43.4_suppl.661","title":"Phase 1b portion of the ACTION-1 phase 1b/3 trial of RYZ101 in gastroenteropancreatic neuroendocrine tumors (GEP-NET) progressing after <sup>177</sup> Lu somatostatin analogue (SSA) therapy: Safety and efficacy findings.","year":2025,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Neuroendocrine Tumor Research Advances","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"ca_institutions":"University of Toronto","funders":"","keywords":"Medicine; Neuroendocrine tumors; Somatostatin; Lanreotide; Internal medicine; Phases of clinical research; Oncology; Phase (matter); Clinical trial; Cancer research; Hormone; Chemistry","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002384441,0.001329869,0.001504725,0.0003992356,0.000299451,0.0008131636,0.0008331656,0.001153457,0.01227079],"category_scores_gemma":[0.001414685,0.0004528629,0.001224506,0.000394805,0.000682866,0.0008973577,0.0003703292,0.003521445,0.001589827],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0009373075,"about_ca_system_score_gemma":0.001725062,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0005451161,"about_ca_topic_score_gemma":0.001792416,"domain_scores_codex":[0.9994109,0.0003272894,0.00002729054,0.0000822874,0.00006462373,0.00008770741],"domain_scores_gemma":[0.9992823,0.0001559283,0.0001977309,0.00006078126,0.00006576366,0.0002375159],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.7973528,0.02297624,0.003942588,0.002170112,0.001692265,0.0002457158,0.0002127515,0.002816823,0.03141039,0.001024555,0.02411502,0.1120408],"study_design_scores_gemma":[0.7756814,0.1988892,0.007743132,0.0001181848,0.0008083594,0.0003912387,0.00004749918,0.001614946,0.004215496,0.0007076517,0.009745762,0.00003722987],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9380601,0.01119262,0.003739984,0.003245588,0.0004651854,0.01656229,0.0143885,0.0005270625,0.01181874],"genre_scores_gemma":[0.9242961,0.004801531,0.01323577,0.00415798,0.0004089854,0.02044372,0.02253203,0.0002257521,0.009898126],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.01227079,"threshold_uncertainty_score":0.04104984,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.0731165879375968,"score_gpt":0.4846606514549349,"score_spread":0.4115440635173381,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}